Description
Vibrenta Vial 3 ml is a long-acting insulin formulation containing 100 IU/ml of insulin glargine, a recombinant human insulin analogue produced by Incepta Pharmaceuticals Ltd. This sterile solution is designed for subcutaneous injection and provides a consistent, peakless insulin effect lasting up to 24 hours, facilitating once-daily dosing. It is indicated for improving glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin glargine regulates glucose metabolism by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and inhibiting hepatic glucose production. The recommended starting dose for type 1 diabetes is approximately one-third of the total daily insulin requirements, with short-acting insulin used to satisfy the remaining needs. For type 2 diabetes, the starting dose is typically 10 units (or 0.2 units/kg) once daily, adjusted based on clinical response. Vibrenta Vial should be administered at the same time each day and is not recommended for intravenous use. Injection sites should be rotated within the same region to reduce
.jpg)
.png)
.jpg)
.jpg)
.webp)
.jpg)
.jpg)
.jpeg)
 400MG.jpg)
 100 IU 3 ML.webp)
.webp)
.jpg)
.jpeg)
.jpeg)
.jpeg)
.jpg)
.webp)
.jpg)
Change Language